Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

SA Transcripts 161.61K Followers Follow Denali Therapeutics Inc. ( DNLI ) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDT Company Participants Laura Hansen Ryan Watts - Co-Founder, President, CEO & Director Katie Peng - Chief Commercial Officer Alexander Schuth - Co-Founder, CFO, COO & Secretary Peter Chin - Acting Chief Medical Officer & Head of Development Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Lin Tsai - Jefferies LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Michael Riad - Morgan Stanley, Research Division Paul Matteis - Stifel Nicolaus Canada Inc., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Jacob Ormes - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Alyssa Larios - Leerink Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Charles Moore - Robert W. Baird & Co. Incorporated, Research Division Presentation Operator Good day and thank you for standing by. Welcome to the second quarter 2026 financial results and business highlights. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Laura Hansen. Please go ahead. Laura Hansen Good afternoon, everyone, and thank you for joining us today to discuss Denali Therapeutics' second quarter 2026 financial results and business highlights. Earlier today, we issued our earnings press release and filed our quarterly report. The press release, financial tables, and today's presentation are available in the Investor Relations section of our website. Before we begin, I would like to remind everyone that today's discussion will include forward-looking statements. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and the